
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Product Name : Kigabeq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : ClinSearch
Deal Size : Inapplicable
Deal Type : Inapplicable
TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Details : Temozolomide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2020
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : ClinSearch
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Temozolomide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules
Details : Temozolomide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Temozolomide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VGB
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VGB is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : VGB
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : INSERM | Hospices Civils de Lyon | National Research Agency, France
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vigabatrin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Spasms, Infantile.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2014
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : INSERM | Hospices Civils de Lyon | National Research Agency, France
Deal Size : Inapplicable
Deal Type : Inapplicable
